Cypress Capital Management (Delaware)’s iShares Biotechnology ETF IBB Stock Holding History

Cypress Capital Management (Delaware)’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,650	Closed	-$215K	–	202
2022 Q1	$215K	Hold	1,650	–	–	0.03%	199
2021 Q4	$252K	Hold	1,650	–	–	0.03%	193
2021 Q3	$270K	Hold	1,650	–	–	0.04%	162
2021 Q2	$270K	Hold	1,650	–	–	0.04%	162
2021 Q1	$248K	Hold	1,650	–	–	0.03%	160
2020 Q4	$250K	Hold	1,650	–	–	0.03%	162
2020 Q3	$223K	Hold	1,650	–	–	0.03%	161
2020 Q2	$226K	Buy	+1,650	New	+$210K	0.04%	156
2018 Q4	–	Sell	-1,650	Closed	-$201K	–	148
2018 Q3	$201K	Buy	+1,650	New	+$194K	0.04%	149
2018 Q2	–	Sell	-1,950	Closed	-$208K	–	152
2018 Q1	$208K	Hold	1,950	–	–	0.04%	139
2017 Q4	$208K	Buy	+1,950	New	+$208K	0.04%	143

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Cypress Capital Management (Delaware)'s IBB Position: Q2 2022 in Review

Cypress Capital Management (Delaware) sold out of iShares Biotechnology ETF (IBB) in Q2 2022, closing a stake of 1,650 shares — an estimated $215K sold.

Cypress Capital Management (Delaware) first reported a position in IBB in Q4 2017 and held it in 11 quarters. The position peaked at $270K in Q3 2021. 858 funds tracked by Wall St. Rank hold IBB as of Q2 2022.

Cypress Capital Management (Delaware) reported no remaining iShares Biotechnology ETF position as of Q2 2022 after selling out during the quarter.
Cypress Capital Management (Delaware) sold 1,650 iShares Biotechnology ETF shares in Q2 2022, an estimated $215K.
Cypress Capital Management (Delaware) first reported a position in iShares Biotechnology ETF in Q4 2017 and held it in 11 quarters.
Cypress Capital Management (Delaware)'s iShares Biotechnology ETF position peaked at $270K in Q3 2021.
858 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2022.

Based on Cypress Capital Management (Delaware)'s 13F filing for Q2 2022, filed 10 Aug 2022.